News

iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing

Princeton, NJ, 28 November, 2023 ─ iQure Pharma Inc, (iQure) a trailblazing pre-clinical drug discovery company focusing on central...

iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital

Princeton, NJ, October 11, 2023 ─ iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain...

iQ-007 Accepted into Prestigious NIH Preclinical Screening Platform for Pain (PSPP) Program

Princeton, NJ, September 5, 2023 ─ iQure Pharma Inc. (iQure), a company dedicated to the development of new epilepsy and pain management...

iQure Pharma’s iQ-007 Completes Critical Go/No Go Criteria - September Start for MTD & GLP Tox Study

Princeton, NJ, August 21, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has completed its key go/no go criteria enabling...

iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy

Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for...

iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone

Princeton, NJ, May 15, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved a major milestone by completing...

iQure Pharma’s iQ-007 & iQ-008 Compounds Continue to Deliver Promising Results

Princeton, NJ, February 24, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, is making significant progress in the...

iQ-007 shows no abuse potential in FDA recommended panel of tests

Princeton, NJ, November 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings...

iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track

iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to...

iQ-007 Considered as First-in-Class Therapeutic Agent in Prestigious Journal of Medicinal Chemistry

International team of scientists share research that demonstrates the effectiveness of iQ-007 and its unique mechanism of action...

iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Neuropathic Pain

DELAWARE, March 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings that...

Novel and promising mechanism of action for new neuropathic pain candidate iQ-007 confirmed

Delaware – November 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, can...

iQ-008 Accepted into NIH Preclinical Screening Platform for Pain (PSPP)

Delaware – May 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, is proud to...

Preliminary Subchronic Toxicology Study Results Indicate iQ-007 Has Favorable Safety Profile

Delaware – September 2020.iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new...

iQ-007: Confirmation of Safety Profile and Second Indication by NINDS (US)

Delaware – January 2020, iQure Pharma Inc., a company dedicated to preclinical and early development of Oncology and Central Nervous...

JPM Week

No Abuse